Table 3.
DALDA part 1 (training day) stress sources | DALDA (part 2 training day) stress symptoms | |||||
RESPONSE | A (Worse) | B (Same) | C (Better) | A (Worse) | B (Same) | C (Better) |
CURCUMIN (n = 11) | 0 (0–3) | 4 (4–9) | 3 (0–5)† | 1 (0–4) | 21(4–25) | 3 (0–19)† |
PLACEBO (n = 11) | 1 (0–5) | 7 (2–9) | 1 (0–6) | 2 (0–7) | 20 (8–25) | 2 (0–15) |
CONTROL (n = 10) | 2 (0–3) | 6 (2–9) | 0 (0–7) | 2 (0–9) | 22 (5–25) | 2 (0–18) |
DALDA part 1 (trial day) stress sources | DALDA part 2 (trial day) stress symptoms | |||||
RESPONSE | A (Worse) | B (Same) | C (Better) | A (Worse) | B (Same) | C (Better) |
CURCUMIN (n = 11) | 2 (0–4) | 6 (2–9) | 1 (0–7) | 2 (0–5) | 22 (5–25) | 1 (0–20) |
PLACEBO (n = 11) | 1 (0–5) | 8 (2–9) | 0 (0–6) | 1 (0–6) | 23 (5–25) | 0 (0–18) |
CONTROL (n = 10) | 2 (0–3) | 7 (3–9) | 0 (0–6) | 3 (0–8) | 22 (4–25) | 1 (0–19) |
Data is grouped according to trial type. A – Worse than usual; B – Same as usual; C – Better than usual. †indicates statistical significant difference between curcumin and placebo trials, p-value in both parts between curcumin and placebo is 0.04 using Wilcoxon signed ranks.